Literature DB >> 10666756

Preserving normal ventricular activation versus atrioventricular delay optimization during pacing: the role of intrinsic atrioventricular conduction and pacing rate.

I I Iliev1, S Yamachika, K Muta, M Hayano, T Ishimatsu, K Nakao, N Komiya, T Hirata, C Ueyama, K Yano.   

Abstract

The purpose of the study was to compare the effects of DDD pacing with optimal AV delay and AAI pacing on the systolic and diastolic performance at rest in patients with prolonged intrinsic AV conduction (first-degree AV block). We studied 17 patients (8 men, aged 69 +/- 9 years) with dual chamber pacemakers implanted for sick sinus syndrome in 15 patients and paroxysmal high degree AV block in 2 patients. Aortic flow and mitral flow were evaluated using Doppler echocardiography. Study protocol included the determination of the optimal AV delay in the DDD mode and comparison between AAI and DDD with optimal AV delay for pacing rate 70/min and 90/min. Stimulus-R interval during AAI (ARI) was 282 +/- 68 ms for rate 70/min and 330 +/- 98 ms for rate 90/min (P < 0.01). The optimal AV delay was 159 +/- 22 ms. AV delay optimization resulted in an increase of an aortic flow time velocity integral (AFTVI) of 16% +/- 9%. At rate 70/min the patients with ARI < or = 270 ms had higher AFTVI in AAI than in DDD (0.214 +/- 0.05 m vs 0.196 +/- 0.05 m, P < 0.01), while the patients with ARI > 270 ms demonstrated greater AFTVI under DDD compared to AAI (0.192 +/- 0.03 m vs 0.166 +/- 0.02 m, P < 0.01). At rate 90/min AFTVI was higher during DDD than AAI (0.183 +/- 0.03 m vs 0.162 +/- 0.03 m, P < 0.01). Mitral flow time velocity integral (MFTVI) at rate 70/min was higher in DDD than in AAI (0.189 +/- 0.05 m vs 0.173 +/- 0.05 m, P < 0.01), while at rate 90/min the difference was not significant in favor of DDD (0.149 +/- 0.05 m vs 0.158 +/- 0.04 m). The results suggest that in patients with first-degree AV block the relative impact of DDD and AAI pacing modes on the systolic performance depends on the intrinsic AV conduction time and on pacing rate.

Entities:  

Mesh:

Year:  2000        PMID: 10666756     DOI: 10.1111/j.1540-8159.2000.tb00652.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  7 in total

Review 1.  First-degree AV block-an entirely benign finding or a potentially curable cause of cardiac disease?

Authors:  Fredrik Holmqvist; James P Daubert
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-05       Impact factor: 1.468

2.  First-degree atrioventricular block. Clinical manifestations, indications for pacing, pacemaker management & consequences during cardiac resynchronization.

Authors:  S Serge Barold; Arzu Ilercil; Fabio Leonelli; Bengt Herweg
Journal:  J Interv Card Electrophysiol       Date:  2007-03-02       Impact factor: 1.900

3.  Dual site right atrial pacing can improve the impact of standard dual chamber pacing on atrial and ventricular mechanical function in patients with symptomatic atrial fibrillation: further observations from the dual site atrial pacing for prevention of atrial fibrillation trial.

Authors:  Atul Prakash; Sanjeev Saksena; Paul D Ziegler; Tasneem Lokhandwala; Douglas A Hettrick; Phillipe Delfaut; Navin C Nanda; D George Wyse
Journal:  J Interv Card Electrophysiol       Date:  2005-04       Impact factor: 1.900

4.  [Avoidance of ventricular pacing in patients with sinus node disease or intermittent AV block].

Authors:  U K H Wiegand
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-03

Review 5.  [Bachmann bundle pacing].

Authors:  C W Israel; T Burmistrava; C Berger
Journal:  Herz       Date:  2018-11       Impact factor: 1.443

6.  Resting sinus heart rate and first degree av block: modifiable risk predictors or epiphenomena?

Authors:  Rakesh Gopinathannair; Brian Olshansky
Journal:  Indian Pacing Electrophysiol J       Date:  2009-11-01

Review 7.  Dual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular block.

Authors:  J Dretzke; W D Toff; G Y H Lip; J Raftery; A Fry-Smith; R Taylor
Journal:  Cochrane Database Syst Rev       Date:  2004
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.